OOIR: Observatory of International Research

Papers

(The H4-Index of Breast Cancer Research and Treatment is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium	233
Patient-reported treatment delays in breast cancer care during the COVID-19 pandemic	152
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer	78
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, T	69
Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies	59
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer	58
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer	57
Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018	56
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment	55
Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival	54
International variation in breast cancer incidence and mortality in young women	53
Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer	51
Evaluation and management of insomnia in women with breast cancer	51
Body composition and breast cancer risk and treatment: mechanisms and impact	46
High-Efficiency Same-Day Approach to Breast Reconstruction During the COVID-19 Crisis	43
Impact of the COVID-19 pandemic on breast cancer screening volumes and patient screening behaviors	43
Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study	41
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence	41
A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns	40
Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection at an academic center in New York City	40
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial	36
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome	34
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)	34
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer	34
Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early	34

Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis	33
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer	33
G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer	32
Peritumoral edema as a biomarker of the aggressiveness of breast cancer: results of a retrospective study on a 3 T scanner	32
Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response	31
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors	30
Financial toxicity and its associated patient and cancer factors among women with breast cancer: a single-center analysis of low-middle income region in China	30
Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy a	30
Behavior of metastatic breast cancer according to subtype	30